Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Mark M. Pomerantz
A Phase 2 Trial of Abiraterone Acetate Without Glucocorticoids for Men With Metastatic Castration-Resistant Prostate Cancer
Cancer
Cancer Research
Oncology
Related publications
Olaparib Combined With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
The Lancet Oncology
Oncology
Exploratory Analysis of the Visceral Disease Subgroup in a Phase III Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer and Prostatic Diseases
Cancer Research
Oncology
Urology
A Prognostic Model for Stratifying Clinical Outcomes in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate
Canadian Urological Association Journal
Urology
Prostate-Specific Antigen Decline After 4 Weeks of Treatment With Abiraterone Acetate and Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer
European Urology
Urology
Mp50-20 Impact of Abiraterone Acetate in Prostate Specific Antigen Trial Update: Effect of Abiraterone Acetate and Low Dose Prednisone on Prostate-Specific Antigen and Radiographic Disease Progression in Patients With Non-Metastatic Castration-Resistant Prostate Cancer
Journal of Urology
Urology
Remarkable Response to Abiraterone Acetate in Castration-Resistant Prostate Cancer Patient With Aggressive Liver Metastasis
IJU Case Reports
Abiraterone in Metastatic Castration-Resistant Prostate Cancer: Efficacy and Safety in Unselected Patients
Cancer Treatment and Research Communications
Cancer Research
Oncology
Phase III Data for Abiraterone in an Evolving Landscape for Castration-Resistant Prostate Cancer
Maturitas
Biochemistry
Gynecology
Genetics
Obstetrics
Molecular Biology
Docetaxel and Dasatinib or Placebo in Men With Metastatic Castration-Resistant Prostate Cancer (READY): A Randomised, Double-Blind Phase 3 Trial
The Lancet Oncology
Oncology